{"id":"W2020431842","doi":"10.1016/j.clml.2012.08.003","title":"An Open-Label Single-Arm Pilot Phase II Study (PX-171-003-A0) of Low-Dose, Single-Agent Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma","year":2012,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":120,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Calgary; Beatrice Hunter Cancer Research Institute; Saint John Regional Hospital; Princess Margaret Cancer Centre; University of Toronto","funders":"Onyx Pharmaceuticals","keywords":"Carfilzomib; Medicine; Multiple myeloma; Bortezomib; Lenalidomide; Internal medicine; Thalidomide; Refractory (planetary science); Adverse effect; Regimen; Clinical endpoint; Phases of clinical research; Proteasome inhibitor; Anemia; Oncology; Surgery; Clinical trial; Gastroenterology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001686316,0.0008714269,0.002014186,0.0004439703,0.0003557291,0.000113972,0.0007808536,0.0004214865,0.0001227134],"category_scores_gemma":[0.001824091,0.0006932717,0.0001391363,0.0007916698,0.000742705,0.001070715,0.0008524708,0.0006386352,0.00005502694],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001745443,"about_ca_system_score_gemma":0.0009343886,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000738723,"about_ca_topic_score_gemma":0.0003684796,"domain_scores_codex":[0.9923425,0.000961781,0.002284077,0.001487654,0.001377948,0.001546051],"domain_scores_gemma":[0.9938057,0.001098783,0.0007853577,0.001840135,0.0004899743,0.001980042],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.02838498,0.1665209,0.5206991,0.000106914,0.0004327616,0.0002772125,0.000610748,0.000001029471,0.002965114,0.00000919063,0.0001493968,0.2798426],"study_design_scores_gemma":[0.1478761,0.1186455,0.7302318,0.0003707744,0.0002401039,0.00002365951,0.0003265729,0.0002526472,0.001085648,0.00001059455,0.000413337,0.0005233036],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.993356,0.0003723918,0.00001102841,0.0000618213,0.0004000418,0.004728295,0.0001396401,0.0001247785,0.0008059687],"genre_scores_gemma":[0.9961042,0.00004726558,0.002124692,0.0002893831,0.000291751,0.0002403725,0.0004281646,0.0001907234,0.0002834359],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2793193,"threshold_uncertainty_score":0.9995518,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09475273562003522,"score_gpt":0.3770711989469108,"score_spread":0.2823184633268755,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}